Search
- Jan 8
Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more
Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval.
- Jan 9, 2023
TCR therapies as a new modality in cancer treatment
Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.